Cost-effectiveness of epinephrine and dexamethasone in children with bronchiolitis

Pediatrics

Volumn 126, Issue 4, 2010, Pages 623-631

  Sumner, Amanda ^a   Coyle, Douglas ^b   Mitton, Craig ^c   Johnson, David W ^d   Patel, Hema ^e   Klassen, Terry P ^f   Correll, Rhonda ^a   Gouin, Serge ^g   Bhatt, Maala ^e   Joubert, Gary ^h   Black, Karen J L ⁱ   Turner, Troy ^f   Whitehouse, Sandra ^c   Plint, Amy C ^b  

^a CHILDREN S HOSPITAL OF EASTERN ONTARIO   (Canada)

^b UNIVERSITY OF OTTAWA   (Canada)

^c UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^d UNIVERSITY OF CALGARY   (Canada)

^e MCGILL UNIVERSITY   (Canada)

^f UNIVERSITY OF ALBERTA   (Canada)

^g UNIVERSITÉ DE MONTRÉAL   (Canada)

^h UNIVERSITY OF WESTERN ONTARIO   (Canada)

ⁱ DALHOUSIE UNIVERSITY   (Canada)

Author keywords

Bronchiolitis; Children; Cost effectiveness; Dexamethasone; Epinephrine; Steroids

Indexed keywords

ADRENALIN; DEXAMETHASONE; PLACEBO; BRONCHODILATING AGENT; GLUCOCORTICOID;

ARTICLE; BREATHING; BRONCHIOLITIS; CHILD CARE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; COUGHING; DOUBLE BLIND PROCEDURE; FEEDING DISORDER; HEALTH CARE SYSTEM; HUMAN; INFANT; INFANT FEEDING; MAJOR CLINICAL STUDY; MONOTHERAPY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SLEEP DISORDER; CANADA; COST BENEFIT ANALYSIS; DRUG COMBINATION; ECONOMICS; HOSPITALIZATION; NEBULIZER; ORAL DRUG ADMINISTRATION; RANDOMIZED CONTROLLED TRIAL (TOPIC);

ADMINISTRATION, ORAL; BRONCHIOLITIS; BRONCHODILATOR AGENTS; COST-BENEFIT ANALYSIS; DEXAMETHASONE; DRUG THERAPY, COMBINATION; EPINEPHRINE; GLUCOCORTICOIDS; HOSPITALIZATION; HUMANS; INFANT; NEBULIZERS AND VAPORIZERS; ONTARIO; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 77957702730     PISSN: 00314005     EISSN: 10984275     Source Type: Journal    
DOI: 10.1542/peds.2009-3663     Document Type: Article

References (34)

1. Shay DK, Holman RC, Newman RD, Liu LL, Stout JW, Anderson LJ. Bronchiolitis-associated hospitalizations among US children, 1980-1996. JAMA. 1999;282(15): 1440-1446
2. Njoo H, Pelletier L, Spika J. Infectious disease. In: Canadian Institute for Health Information, Canadian Lung Association, Health Canada, Statistics Canada, eds. Respiratory Disease in Canada. Toronto, Ontario, Canada: Canadian Institute for Health Information; 2001:65-87
3. Langley JM, Wang EEL, Law BJ, et al. Economic evaluation of respiratory syncytial virus infection in Canadian children: a Pediatric Investigators Collaborative Network on Infections in Canada (PICNIC) study. J Pediatr. 1997;131(1):113-117 (Pubitemid 27498318)
4. Plint AC, Johnson DW, Wiebe N, et al. Practice variation among pediatric emergency departments in the treatment of bronchiolitis. Acad Emerg Med. 2004;11(4):353-360
5. Stang P, Brandenburg N, Carter B. The economic burden of respiratory syncytial virus-associated bronchiolitis hospitalizations. Arch Pediatr Adolesc Med. 2001; 155(1):95-96
6. Kamal-Bahl S, Doshi J, Campbell J. Economic analyses of respiratory syncytial virus immunoprophylaxis in high-risk infants, a systematic review. Arch Pediatr Adolesc Med. 2002;156(10):1034-1041
7. Yong JH, Schuh S, Rashidi R, et al. A cost effectiveness analysis of omitting radiography in diagnosis of acute bronchiolitis. Pediatr Pulmonol. 2009;44(2):122-127
8. Tugwell P, Bennett KJ, Sackett DL, Haynes RB. The measurement iterative loop: a framework for the critical appraisal of need, benefits and costs of health interventions. J Chronic Dis. 1985;38(4): 339-351 (Pubitemid 15044152)
9. Hartling L, Scott-Findlay S, Johnson D, et al; Canadian Institutes for Health Research Team in Pediatric Emergency Medicine. Bridging the gap between clinical research and knowledge translation in pediatric emergency medicine. Acad Emerg Med. 2007;14(11):968-977
10. Klassen TP. Economic evaluations of immunoprophylaxis in infants at high risk for respiratory syncytial virus: shedding light or creating confusion? Arch Pediatr Adolesc Med. 2002;156(12):1180-1181
11. Plint AC, Johnson DW, Patel H, et al; Pediatric Emergency Research Canada (PERC). Epinephrine and dexamethasone in children with bronchiolitis. N Engl J Med. 2009; 360(20):2079-2089
12. Greening AP, Ind PW, Northfield M, Shaw G. Added salmeterol versus higher-dose corticosteroid in asthma patients with symptoms on existing inhaled corticosteroid. Allen & Hanburys Limited UK Study Group. Lancet. 1994;344(8917):219-224
13. Pauwels RA, Löfdahl CG, Postma DS, et al. Effect of inhaled formoterol and budesonide on exacerbations of asthma. Formoterol and Corticosteroids Establishing Therapy (FACET) International Study Group [published correction appears in N Engl J Med. 1998;338(2):139]. N Engl J Med. 1997; 337(20):1405-1411
14. Barnes PJ. Scientific rationale for using a single inhaler for asthma control. Eur Respir J. 2007;29(3):587-595
15. Giembycz MA, Kaur M, Leigh R, Newton R. A Holy Grail of asthma management: toward understanding how long-acting beta(2)-adrenoceptor agonists enhance the clinical efficacy of inhaled corticosteroids. Br J Pharmacol. 2008;153(6):1090-1104
16. Mak JC, Nishikawa M, Barnes PJ. Glucocorticosteroids increase beta 2-adrenergic receptor transcription in human lung. Am J Physiol. 1995;268(1 pt 1):L41-L46
17. Roth M, Johnson PR, Rudiger JJ, et al. Interaction between glucocorticoids and beta2 agonists on bronchial airway smooth muscle cells through synchronised cellular signalling. Lancet. 2002; 360(9342):1293-1299
18. Kaur M, Chivers JE, Giembycz MA, Newton R. Long-acting beta2-adrenoceptor agonists synergistically enhance glucocorticoid-dependent transcription in human airway epithelial and smooth muscle cells. Mol Pharmacol. 2008;73(1):203-214 (Pubitemid 350294211)
19. Kuyucu S, Unal S, Kuyucu N, Yilgor E. Additive effects of dexamethasone in nebulized salbutamol or L-epinephrine treated infants with acute bronchiolitis. Pediatr Int. 2004; 46(5):539-544 (Pubitemid 39423198)
20. Bentur L, Shoseyov D, Feigenbaum D, Gorichovsky Y, Bibi H. Dexamethasone inhalations in RSV bronchiolitis: a double-blind, placebo-controlled study. Acta Paediatr. 2005;94(7):866-871
21. Tal A, Bavilski C, Yohai D, Bearman JE, Gorodischer R, Moses SW. Dexamethasone and salbutamol in the treatment of acute wheezing in infants. Pediatrics. 1983;71(1):13-18
22. Lowell DI, Lister G, Von Koss H, McCarthy P. Wheezing in infants: the response to epinephrine. Pediatrics. 1987;79(6):939-945
23. Schuh S, Coates AL, Binnie R, et al. Efficacy of oral dexamethasone in outpatients with acute bronchiolitis. J Pediatr. 2002;140(1): 27-32
24. McBride JT. Dexamethasone and bronchiolitis: a new look at an old therapy? J Pediatr. 2002;140(1):8-9 (Pubitemid 34117459)
25. Patel H, Platt RW, Pekeles GS, Ducharme FM. A randomized, controlled trial of the effectiveness of nebulized therapy with epinephrine compared with albuterol and saline in infants hospitalized for acute viral bronchiolitis. J Pediatr. 2002;141(6): 818-824
26. Patel H, Gouin S, Platt RW. Randomized, double-blind, placebo-controlled trial of oral albuterol in infants with mild-to-moderate acute viral bronchiolitis. J Pediatr. 2003;142(5):509-514 (Pubitemid 36623560)
27. Gaboury I, O'Grady K, Coyle D, Le Saux N. Treatment cost-effectiveness in acute otitis media: watch-and-wait versus amoxicillin. Paediatr Child Health. 2010; In press
28. Ministry of Health and Long-term Care. Available at: www.health.gov.on. ca/english/providers/program/ohip/sob/sob-mn. html. Accessed March 10, 2009
29. Ministry of Health and Long-term Care. Ontario drug benefit formulary/comparative drug index. Available at: www.health.gov.on.ca/ english/providers/program/drugs/odbf-mn. html (search: www.healthinfo.moh.gov. on.ca/ formulary). Accessed March 10, 2009
30. Canadian Automobile Association. Driving costs. Available at: www.smartcommuteexpo. ca/DrivingCostsBrochure08.pdf. Accessed March 10, 2009
31. Campbell MK, Torgerson DJ. Bootstrapping: estimating confidence intervals for cost-effectiveness ratios. QJM. 1999;92(3): 177-182
32. Glick H, Doshi JA, Sonnad SS, Polsky D. Economic Evaluation in Clinical Trials. Oxford, England: Oxford University Press; 2007
33. Fenwick E, Claxton K, Sculpher M. Representing uncertainty: the role of costeffectiveness acceptability curves. Health Econ. 2001;10(8):779-787 (Pubitemid 34041389)
34. Eisenberg MJ, Filion KB, Azoulay A, Brox AC, Haider S, Pilote L. Outcomes and cost of coronary artery bypass graft surgery in the United States and Canada. Arch Intern Med. 2005;165(13):1506-1513